Jeremie Fastnacht argues flavour and fragrance drive why people buy products more than advertising, packaging or price, making Givaudan a largely unseen business.
Fastnacht says clients rarely change successful formulas because a 1% change saves little and carries safety and brand risk, creating high switching costs.
Fastnacht calls Givaudan's stock, at about 23 times free cash flow with only about 3% implied growth, too low for a business with 5% organic growth history.
Givaudan sells flavours and scents that decide whether consumers love a product, yet they cost clients only 1 to 5% of their spend. Winning formulas rarely get replaced, so revenue recurs and margins hold. A concentrated market and heavy R&D keep rivals competing on innovation rather than price.
Takeaways
Scent and taste drive why people buy products. Fastnacht says studies show flavour and fragrance matter more to why people love a product than advertising, packaging or price. Givaudan ingredients sit in tens of thousands of products, making the industry a staples business but better, with defensive recurring demand.
Switching costs lock in clients once formulas win. Clients send a brief with a target price, and three or four suppliers pitch unpaid. The winning compound is unique and stays with the supplier, like a royalty with upfront cost. A 1% saving rarely justifies the safety and brand risk of changing.
Tiny cost share gives pricing resilience. Flavour is about 1% of a client's cost and fragrance about 5%, so procurement pushes for rebates, while suppliers negotiate to pass on raw material inflation. Selling something critical for a small share of cost gives durable margins and visibility.
Concentrated fragrance market rewards scale and innovation. Givaudan, Firmenich, IFF and Symrise hold about two-thirds of fragrance, while flavour leaders hold around 10% each. Rivals compete on innovation, not price. Givaudan loses about 10% of revenue yearly, so it needs 15% new products to grow 5%.
Givaudan leads on scale, IP and talent. It holds about 25% of fine fragrance and 10 to 15% of flavour. It spends about 8% of sales on R&D and holds 5,000 patents. Fragrance and beauty margin is rising to 27%, while taste and wellbeing holds near 22%.
Steady growth and cash, but valuation implies little. Organic growth ran about 5% before COVID, typically 4% volume and 1% price, with no negative year since the IPO. Operating margin is 18 to 19% and free cash flow tops 1bn francs. At 23 times free cash flow, Fastnacht sees only 3% growth priced in.
How Givaudan became the leader
In 1895 brothers Léon and Xavier Givaudan found a perfume factory in Zurich, then move to Vernier and pioneer synthetic perfume in large quantity.
In 1948 it buys Esrolko to enter flavour.
In the 1960s Roche acquires Givaudan and Roure of Grasse, and merges them in the 1990s.
In 2000 it is spun off and listed on the Swiss exchange.
In the early 2000s it buys Nestlé Food Ingredients, and later Quest International from Unilever.
Tap a name to go there · tap a line to see why they are linked
On this episode 2
Show 1
Risks Fastnacht names
Management change, with Gilles Andrier retired as CEO but still chairman, CFO Tom Hallam gone and a new CEO from March.
An antitrust investigation of several fragrance players around 2023.
Chinese price competition in commoditised ingredients.
Middle East exposure of 7 to 8% of sales, and more volatile fine fragrances at 11% of sales.